Jean-François Pariseau
Board Member @ Clementia Pharmaceuticals
Montréal, Canada
Jean-François Pariseau is a Series A investor at Clementia Pharmaceuticals in Montréal focused on Medical and Biotechnology. Jean-François Pariseau is the Co-Founder and Partner of Amplitude Venture Capital & he attended Université de Montréal in 1992.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Jean-François Pariseau invests in
Stages Jean-François Pariseau invests in
Countries Jean-François Pariseau invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 5 (38%)
- Biotechnology 5 (38%)
- Health Care 4 (31%)
- Biopharma 2 (15%)
- Therapeutics 2 (15%)
Stage
- Series A 5 (38%)
- Funding Round 4 (31%)
- Seed 1 (8%)
- Post-IPO Equity 1 (8%)
- Convertible Note 1 (8%)
Country
- Canada 7 (54%)
- United States 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Thryv Therapeutics
|
Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. | Sep 17, 2025 | |
Fluid Biomed
|
Fluid Biotech is a Calgary based company that aims to develop the next generation of stents to improve patient well-being and realise better health and quality of life through innovation. | $27M / Series A / Dec 16, 2024 | |
|
Thryv Therapeutics
|
Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. | $19M / Series A / Aug 10, 2021 | |
Giiant Pharma
|
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M / Seed / May 21, 2021 | |
Zymeworks
|
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases.Zymeworks' approach combines proprietary molecular modeling andsimulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.It was founded in 2004 and headquartered in Vancouver, British Columbia. | Post-IPO Equity / Nov 06, 2019 | |
Imagia
|
Imagia's mission is to leverage advances in artificial intelligence and accelerate the advent of accessible personalized medicine.The company's platform leverage advances in artificial intelligence to provide outcome-based structured clinical data and federated learning capabilities across multiple sources while preserving privacy,enabling clinicians to drive end-to-end discoveries of predictive, diagnostic, and prescriptive analytics. | $2.9M / Series A / Jan 01, 2018 | |
Clementia Pharmaceuticals
|
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shownpotent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. | $60M / Jun 23, 2015 | |
Profound Medical Inc
|
The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patientsand clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives. | $20.1M / Apr 30, 2015 | |
|
Profound Medical Inc
|
The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patientsand clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives. | $1.1M / Convertible Note / Jan 27, 2015 | |
|
Clementia Pharmaceuticals
|
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shownpotent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. | $10M / Series A / Jan 05, 2015 | |
| See all 13 investments → | |||
Co-Investors
About Clementia Pharmaceuticals
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shownpotent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.
Clementia Pharmaceuticals Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jean-François Pariseau
Board Member
|
|||
Michael Singer
Chief Financial Officer
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jean-François Pariseau invest in?
Jean-François Pariseau invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Funding Round stage. Most of the 13 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jean-François Pariseau?
Public channels for Jean-François Pariseau include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jean-François Pariseau last invest?
The most recent investment recorded for Jean-François Pariseau closed in Sep 2025. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
